Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21042903 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2FKBP1AALDH1A1GAAHTT | |
| SCHEMBL15932274 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2FKBP1AALDH1A1GAAHTT | |
| SCHEMBL19695784 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13515717 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL21042359 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2FKBP1AALDH1A1GAAHTT | |
| SCHEMBL21042296 | 0.77 | KDM4E (0.43) | SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL35889 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1TP53POLB | |
| SCHEMBL10049540 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1TP53POLB | |
| SCHEMBL16718949 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1TP53POLB | |
| SCHEMBL10049180 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-03-03 | — | — | US | disclosed |
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | CYP3A7, CYP2A7, CYP2J2 | SMN1; SMN2 2717/4885FKBP1A 911/4885ALDH1A1 424/4885 |
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | CYP3A7, UGT2B7, BDKRB1 | SMN1; SMN2 2759/4885FKBP1A 1438/4885ALDH1A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.